- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about KONEF
Recent news which mentions KONEF
World's Largest Psychedelics Conference Sheds Light On Alternative Mental Health Therapies, Boasts 12K Attendees
June 26, 2023
Tickers
KONEF
From Benzinga
Psyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & More
March 13, 2023
From Benzinga
Another Company Approved To Begin Production Of Psychedelics Under Canadian Dealers License
March 09, 2023
Tickers
KONEF
From Benzinga
Who's Who At The Benzinga Psychedelics Capital Conference? Check Out These CEOs & Meet Them In Person
March 08, 2023
From Benzinga
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
February 21, 2023
From Benzinga
From Benzinga
Women's Footprint In Psychedelics Is Undeniable, Benzinga's Psychedelics Advisory Council's Six New Trailblazers
January 30, 2023
From Benzinga
First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval
December 27, 2022
From Benzinga
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
December 06, 2022
From Benzinga
Psychedelic Partnership To Test Psilocybin For FXS In First Phase 2 Clinical Trial
November 30, 2022
From Benzinga
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
November 21, 2022
From Benzinga
Psychedelics For FXS Symptoms: New Research Contract For Upcoming Phase 2 Clinical Trial
November 17, 2022
From Benzinga
Successful Study On Transdermal CBD & THC Delivery Presents Benefits For Treating Chronic Conditions
November 15, 2022
Tickers
KONEF
From Benzinga
Psyched: Top Psychedelics Execs., 50% Of Americans Support Medical Psychedelics, Cary Grant's LSD Therapy & More
November 01, 2022
From Benzinga
Pathway Health To Acquire IRP Health From Wellbeing Digital Sciences
October 27, 2022
Tickers
KONEF
From Benzinga
Psyched: CA's Psychedelic-Assisted Treatments, Ketamine Therapy, Near-Death Experience And More
October 07, 2022
From Benzinga
Ketamine Therapy At Your Doorstep, Growing Number Of Clinics Offer This Treatment Option
October 05, 2022
From Benzinga
Wellbeing Digital Reports 4Q Finances, 'Three Key Pillars' Stay Strong
September 16, 2022
Tickers
KONEF
From Benzinga
World Class Leaders In Psychedelics Form Benzinga's Psychedelic Advisory Council—Get To Know Them
August 30, 2022
From Benzinga
KGK Sciences And Halucenex Sign Contract For Phase II Clinical Trial On Psilocybin For PTSD
July 21, 2022
From Benzinga
Wellbeing Digital Introduces Women In Psychedelics, A Network For Female Minds In Psychedelics
July 18, 2022
Tickers
KONEF
From Benzinga
From Benzinga
From Benzinga
Psychedelic Stock Gainers And Losers From March 7, 2022
March 07, 2022
From Benzinga
Psychedelic Stock Gainers And Losers From March 4, 2022
March 04, 2022
From Benzinga
Psychedelic Stock Gainers And Losers From March 1, 2022
March 01, 2022
From Benzinga
Psychedelic Stock Gainers And Losers From February 28, 2022
February 28, 2022
From Benzinga
Psychedelic Stock Gainers And Losers From February 14, 2022
February 14, 2022
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.